Boisey O Barnes, MD in Wash, DC - Medicare Cardiovascular Disease (cardiology)

Boisey O Barnes, MD is a medicare enrolled "Internal Medicine - Cardiovascular Disease" physician in Wash, District Of Columbia. He went to Howard University College Of Medicine and graduated in 1968 and has 56 years of diverse experience with area of expertise as Cardiovascular Disease (cardiology). His current practice location is 1150 Varnum St, Providence Hospital, Wash, District Of Columbia. You can reach out to his office (for appointments etc.) via phone at (202) 269-7118.

Boisey O Barnes is licensed to practice in District Of Columbia (license number MD5168) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1942358569.

Contact Information

	Boisey O Barnes, MD
	1150 Varnum St, Providence Hospital, Wash, DC 20017
	(202) 269-7118
	Not Available

Physician's Profile

Full Name	Boisey O Barnes
Gender	Male
Speciality	Cardiovascular Disease (cardiology)
Experience	56 Years
Location	1150 Varnum St, Wash, District Of Columbia
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Boisey O Barnes attended and graduated from Howard University College Of Medicine in 1968

NPI Data:

NPI Number: 1942358569
Provider Enumeration Date: 01/08/2007
Last Update Date: 07/06/2010

Medicare PECOS Information:

PECOS PAC ID: 7911160205
Enrollment ID: I20120530000150

Medical Identifiers

Medical identifiers for Boisey O Barnes such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1942358569	NPI	-	NPPES
021483900	Medicaid	DC

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RC0000X	Internal Medicine - Cardiovascular Disease	MD5168 (District Of Columbia)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Medstar Washington Hospital Center	Washington, DC	Hospital

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Boisey O Barnes is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Boisey O Barnes, MD 4700 Berwyn House Rd, Suite 207, College Park, MD 20740 Ph: (301) 220-0150	Boisey O Barnes, MD 1150 Varnum St, Providence Hospital, Wash, DC 20017 Ph: (202) 269-7118

News Archive

Research: Interval-based team sport can make up for oestrogen loss

When women enter menopause, their oestrogen levels taper. This increases their risk of cardiovascular disease. New research from University of Copenhagen shows that interval-based team sport can make up for this oestrogen loss as it improves their conditions, reduces blood pressure and thereby protects the cardiovascular system.

RegenceRx supports DEA program to raise awareness on unused prescription drugs

In a nationwide effort to clear homes of potentially dangerous, expired, unused, and unwanted prescription drugs, RegenceRx is supporting the Drug Enforcement Administration's National Prescription Drug Take-Back Day taking place on Saturday, April 30.

Pfizer donates £1 million Brighton and Sussex Medical School

Brighton and Sussex Medical School (BSMS) is pleased to announce that it has received a £1 million donation from pharmaceutical company, Pfizer (UK).

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

Boisey O Barnes, MD - Medicare Cardiovascular Disease (cardiology) in Wash, DC